Latest VRCA news and sentiment

West Chester's Verrica Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial for YCANTH® in Common Warts

Verrica Pharmaceuticals has completed enrollment in COVE-2, the first of two pivotal Phase 3 trials for YCANTH® (VP-102, cantharidin) to treat common warts, with topline data expected in Q1 2027. This drug is already FDA-approved for molluscum contagiosum, and its expansion to common warts, which affects 22 million people in the U.S. and lacks an FDA-approved prescription treatment, represents a potential multibillion-dollar opportunity. The company is partnering with Torii Pharmaceutical, which is sharing Phase 3 costs.

Verrica Completes Enrollment in Phase 3 YCANTH Common Warts Trial

Verrica Pharmaceuticals has completed enrollment in COVE-2, its first pivotal phase 3 trial for YCANTH in treating common warts, with topline data expected in Q1 2027. COVE-3, the second pivotal trial, has exceeded 50% enrollment. If successful, YCANTH could be the first FDA-approved prescription treatment for common warts, representing a significant commercial opportunity given the 22 million affected patients in the US.

Verrica completes enrolment in Phase III trial of Ycanth

Verrica Pharmaceuticals has completed patient enrolment for COVE-2, the first pivotal Phase III trial for its Ycanth (VP-102) treatment for common warts. Top-line data for this trial are expected in Q1 2027. The company is also ahead of schedule for enrolment in its second pivotal trial, COVE-3, and is collaborating with Torii Pharmaceutical on the global Phase III program to seek marketing approval in the US and Japan.

Verrica (VRCA) Results Versus Estimates: The Bottom-Line Figure Trails Its Comparison in the Current Update; Share Move: Shares Move 1.04% Up at the Close - Dividend Increase Stocks

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

Analysts have issued a consensus "Hold" rating for Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), with an average 12-month price target significantly higher than its current trading price. Institutional investors and hedge funds hold a substantial portion of the company's stock, with many increasing their positions recently. Verrica Pharmaceuticals is a clinical-stage biopharmaceutical company focused on topical dermatological treatments, including its lead candidate VP-102.

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

Verrica Pharmaceuticals CEO Jayson Rieger recently purchased 5,000 shares of the company's stock for $24,550, increasing his total ownership to 207,593 shares. This transaction occurred as the stock fell 4.3% to $4.68, bringing its market capitalization to approximately $80.4 million. The company has mixed analyst sentiment, holding an average "Hold" rating with a target price of $14.50.

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

Verrica Pharmaceuticals' (NASDAQ:VRCA) Chief Marketing Officer, Noah Rosenberg, purchased 4,200 shares of the company's stock for $20,622, increasing his direct ownership by 178.19%. This transaction occurred as VRCA shares traded down, below their 50-day and 200-day moving averages. The company holds an $80.4 million market capitalization, with a mixed analyst consensus of "Hold" and a $14.50 price target.

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per share, beating estimates, and revenue of $5.02 million, exceeding expectations.

Verrica Pharmaceuticals (VRCA) Holds Steady at $5.08 as Range Trade Persists - Rounding Bottom

Verrica Pharmaceuticals Q2 Earnings Call Highlights

Verrica Pharmaceuticals reported significant Q2 revenue growth for its YCANTH treatment, achieving $5.1 million in U.S. net product revenue. The company also provided updates on its common warts program, with pivotal Phase III trials underway and top-line results expected in mid-2027. Additionally, Verrica announced a new credit facility and international distribution agreement, aiming to extend its cash runway and expand YCANTH's global reach.

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) reported a wider-than-expected adjusted loss of $0.48 per share for the quarter, though revenue slightly exceeded forecasts at $5.86 million. The company saw strong sequential growth in YCANTH dispensed units and net product revenue, and began dosing patients in a pivotal common-warts trial. Despite increased YCANTH sales, total revenue decreased year-over-year due to the absence of a prior-period milestone payment, and higher spending led to a significant GAAP net loss.

Verrica secures $27.5 million credit facility from chairman By Investing.com

Verrica Pharmaceuticals Inc. announced a $27.5 million credit facility with an entity controlled by its chairman and largest shareholder, Paul B. Manning. This financing includes an immediate $12.5 million and an additional $15 million upon reaching specific milestones. The funds will support the commercialization of YCANTH and general corporate operations, potentially extending the company's cash runway into 2028.

Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings

YCANTH applicator units reach 19,626; common-wart data expected mid-2027

Verrica Pharmaceuticals reported Q2 2026 total revenue of $5.9 million, down from $12.7 million year-over-year, largely due to the absence of a one-time milestone payment. Despite this, U.S. YCANTH net product revenue grew to $5.1 million, with dispensed YCANTH applicator units increasing by 46.1% year-over-year to 19,626 units. The company secured a new credit facility of up to $27.5 million, which it believes could extend its cash runway into 2028, and anticipates topline data from its global Phase 3 common warts program by mid-2027.

New funding supports Verrica's global Phase 3 common-warts program

Verrica Pharmaceuticals (Nasdaq: VRCA) has secured a new credit facility of up to $27.5 million in non-dilutive growth capital from an entity controlled by its Chairman, Paul B. Manning. This financing aims to support the commercialization of YCANTH, fund the global Phase 3 common warts program with data expected by mid-2027, and cover general corporate purposes. The facility is expected to extend Verrica's cash runway into 2028 and offers potential for no scheduled principal or interest payments until its maturity on December 31, 2030, under certain conditions.

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

Verrica Pharmaceuticals Inc. announced its Q2 2026 financial results, reporting a record demand for YCANTH® with 19,626 dispensed applicator units, an increase of 28.3% quarter-over-quarter and 46.1% year-over-year. Total revenue reached $5.9 million, including $5.1 million in U.S. YCANTH net product revenue. The company also secured a new credit facility for up to $27.5 million, extending its cash runway into 2028, and anticipates topline data from its Phase 3 common warts program in mid-2027.